PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩6,000 per share · Prices as of the 2026-10-02 close
As the domestic cigarette market shrinks, overseas cigarettes and domestic next-generation products (NGP) are carrying profit growth, while the company has raised full-year guidance and expanded dividends and share cancellations.
For FY2025, revenue reached KRW 6,579.7bn and operating profit KRW 1,343.7bn, with an operating margin of 20.4%.
Q2 2026 revenue of KRW 1,701.6bn and operating profit of KRW 414.5bn rose 9.9% and 18.5% year on year, prompting the company to raise full-year guidance.
The growth drivers are simultaneous price and volume gains in overseas cigarettes plus a richer premium mix in domestic NGP.
In April 2026 the company cancelled all treasury shares it held, equal to 9.5% of issued shares, and plans to unveil a new mid-to-long-term shareholder return policy in Q4.
On the other side, declining domestic cigarette demand, weak overseas health-functional-food sales, a rising debt ratio and shrinking operating cash flow are offsetting concerns.
KT&G runs a portfolio spanning tobacco, health functional foods through KGC Ginseng Corp, and real estate, with tobacco further split into domestic cigarettes, overseas cigarettes and next-generation products (NGP).
In Q2 2026 the tobacco division posted revenue of KRW 1,218.5bn, up 11.7% year on year, and operating profit of KRW 382.5bn, up 18.8%. Domestic cigarettes held the top position with a 67.9% first-half market share, while NGP held a 48.2% domestic share.
Overseas cigarettes grew despite geopolitical uncertainty, with Q2 revenue and operating profit up 18.9% and 45.6% respectively.
In Q1 as well, volume growth across Asia-Pacific and Eurasia plus strategic price increases lifted overseas cigarette revenue to a quarterly record KRW 559.6bn, with operating profit up 56.1%.
Abroad the company operates local plants producing and selling core brands such as ESSE and BOHEM, and 2024 global volumes were 58.6bn cigarette sticks plus 8.3bn NGP sticks. NGP is currently sold mainly through a partnership with Philip Morris International, with only a portion sold directly.
In health functional foods, Q2 domestic sales rose 7.8% to KRW 174.2bn while overseas sales came in at KRW 49.6bn amid Chinese channel inventory adjustment; segment operating profit still jumped 61.3% to KRW 10.0bn on a shift to higher-margin channels.
Competition comes from the Korean units of global players such as Philip Morris Korea, BAT and JTI at home, and from the same global majors region by region abroad.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.5T | ₩349.9B | 22.6% |
| 2025Q3 | ₩1.8T | ₩465.3B | 25.5% |
| 2025Q4 | ₩1.7T | ₩242.9B | 14.2% |
| 2026Q1 | ₩1.7T | ₩364.5B | 21.4% |
| 2026Q2 | ₩1.7T | ₩414.5B | 24.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩5.9T | ₩1.3T | ₩1T | 21.7% | 10.9% | 31.4% |
| 2023 | ₩5.9T | ₩1.2T | ₩902.7B | 19.9% | 9.8% | 37.4% |
| 2024 | ₩5.9T | ₩1.2T | ₩1.2T | 20.1% | 12.6% | 48.8% |
| 2025 | ₩6.6T | ₩1.3T | ₩1.1T | 20.4% | 11.7% | 52.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
On an annual basis, revenue was essentially flat at KRW 5,851.4bn in 2022, KRW 5,862.6bn in 2023 and KRW 5,908.8bn in 2024 before stepping up clearly to KRW 6,579.7bn in 2025.
Operating profit also rose from KRW 1,167.3bn in 2023 and KRW 1,188.8bn in 2024 to KRW 1,343.7bn in 2025, while the operating margin slipped from 21.7% in 2022 to 19.9% in 2023 and then recovered to 20.1% and 20.4%.
Net profit attributable to owners, however, fell from KRW 1,165.7bn in 2024 to KRW 1,090.1bn in 2025, so operating-level gains did not flow straight through to the bottom line. Quarterly data show wide swings from seasonality and non-operating items.
In Q2 2025 operating profit of KRW 349.9bn compared with only KRW 143.3bn of owners' net profit; Q3 2025 marked the strongest quarter in the recent window with revenue of KRW 1,826.9bn and operating profit of KRW 465.3bn; and Q4 2025 saw operating profit drop to KRW 242.9bn on revenue of KRW 1,713.8bn.
Into 2026, Q1 revenue of KRW 1,703.6bn with operating profit of KRW 364.5bn and Q2 revenue of KRW 1,701.6bn with operating profit of KRW 414.5bn pushed margins back toward the mid-20% range, and Q2 operating profit was up 18.5% from KRW 349.9bn a year earlier.
Owners' net profit also recovered sharply to KRW 380.5bn in Q1 2026 and KRW 364.3bn in Q2, versus KRW 143.3bn a year before. The Q1 improvement was attributed to an 8% rise in overseas cigarette average selling prices alongside a 15% increase in volumes.
Meanwhile operating cash flow narrowed from KRW 1,266.0bn in 2023 to KRW 822.3bn in 2024 and KRW 582.9bn in 2025, and the debt ratio climbed from 31.4% in 2022 to 52.0% in 2025, so profit growth and cash-and-balance-sheet metrics are pointing in different directions.
Korea's domestic tobacco market is in a structurally shrinking phase. One brokerage analysis noted the domestic cigarette market contracted 5.2% in Q1 2026 on lower total demand and migration to NGP, while KT&G lifted its share to 68.8% through new launches.
As the market shifts rapidly toward NGP, headroom for conventional cigarettes is limited, and cannibalization of existing cigarette profits accompanies NGP expansion. Overseas, by contrast, is the growth axis.
Hanwha Investment & Securities said in a May 2026 report that with new plants in Kazakhstan (Q2 2025) and Indonesia (Q1 2026), more than 50% of overseas sales volume would be produced abroad in 2026, allowing manufacturing and logistics cost savings that could improve profitability.
On regulation, the Act on Management of Tobacco Harmfulness took effect on 1 November 2025, requiring manufacturers and importers to submit products for harmful-ingredient testing every two years.
In April 2026 the legal definition of tobacco was broadened from products using tobacco leaf to products using tobacco or nicotine, the first such change since the Tobacco Business Act was enacted in 1988.
The result is a two-track picture: shrinking demand and tightening rules at home, versus local production and pricing power driving results abroad.
The company's own direction is condensed in its raised guidance. Alongside Q2 results, KT&G lifted its full-year revenue growth outlook from 3-5% to 5-7% and its operating profit growth outlook from 6-8% to 10-13%.
Senior Executive Vice President Lee Sang-hak said a sharp increase in overseas operating profit and strong domestic NGP momentum drove the simultaneous rise in revenue and operating profit. Shareholder-return timing is another checkable event.
The company said it will announce a new mid-to-long-term shareholder return policy featuring stronger dividends in the fourth quarter, and that new treasury share buybacks and cancellations planned for the second half will proceed as scheduled.
On expansion, management has flagged a standalone global rollout of heat-not-burn products leveraging its overseas distribution know-how, while a brokerage report noted the long-term supply agreement with PMI entering a second phase, with direct launches planned first in Asia-Pacific and Eurasia.
In health functional foods, the company outlined a dedicated global nutrition center and a business-to-business red ginseng ingredient operation as part of overseas diversification, and in September 2025 it signed a comprehensive memorandum of understanding with Altria of the United States covering global nicotine and non-nicotine markets, positioning nicotine pouches as a new growth driver.
Still, the timing of a recovery in overseas health-food sales that fell on Chinese channel inventory adjustment remains unconfirmed.
Assessing this stock's multiples requires looking at both the direction of profit and the change in share count. In April 2026 the company cancelled its entire holding of 10,866,189 treasury shares, equal to 9.5% of issued shares, and cumulative cancellations amount to 14.3% of the share count as of end-2023.
Because cancellations shrink the share base, per-share metrics improve on the same profit, and the multiple based on the last four quarters of earnings has been forming above the band that applied when the company was viewed purely as a domestic cigarette play.
Against book value the shares trade at a premium to net asset value per share, and the payout structure combines a year-end dividend with an interim dividend, with the board in August 2026 approving an interim dividend raised from the prior year.
On the brokerage side, Yuanta Securities said in a July 2026 report that it raised its target price to KRW 250,000 and maintained a buy rating, while DS Investment & Securities said in a May 2026 report that it set a target price of KRW 210,000, applying a target multiple of 15 times 2026 earnings.
Ultimately the multiple debate hinges on whether overseas cigarette price and mix gains persist, and on the scale of the new shareholder return policy due in the fourth quarter.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
In Q1 2026 overseas cigarette average selling prices rose 8% while volumes grew 15%, lifting revenue and operating profit 25% and 56% respectively. Q2 continued with revenue up 18.9% and operating profit up 45.6% despite geopolitical uncertainty.
Simultaneous price and volume growth is generally read as evidence that cost inflation can be passed through. This trend is increasingly offsetting the decline in domestic cigarette demand.
Hanwha Investment & Securities said in a May 2026 report that with the Kazakhstan and Indonesia plants running, more than half of overseas sales volume would be produced locally in 2026, enabling manufacturing and logistics cost savings.
The Indonesian plant was described as a base for extending the supply chain from Southeast Asia to the Middle East. Shifting from export shipments toward local production also changes sensitivity to currency and freight swings. The actual savings, however, depend on utilization rates and regional pricing.
In April 2026 the company cancelled all 10,866,189 treasury shares it held, equal to 9.5% of issued shares. It also stopped permanently holding treasury shares for employee compensation, buying and immediately disposing of them so that company-held treasury stock stays at zero.
A new mid-to-long-term return policy with stronger dividends is due in the fourth quarter, and second-half buybacks and cancellations remain on schedule. Cancellations reduce the share count and therefore work structurally on per-share metrics.
Analysis indicated the domestic cigarette market shrank 5.2% in Q1 2026 on lower total demand and migration to NGP. Commentary has also stressed that headroom for conventional cigarettes is limited as the market itself moves toward NGP.
Domestic cigarettes are a high-margin pillar, so volume declines feed directly into mix. Defending market share does not reverse the contraction of the market itself.
Q2 overseas health-food sales came in at KRW 49.6bn, down KRW 9.4bn year on year on Chinese channel inventory adjustment. Domestic growth was helped by May family-month promotions and brand campaigns.
Commentary noted that behind strong tobacco and NGP growth, weak overseas health foods and structural limits in the domestic market remain risks. Promotion-led growth makes durability harder to judge.
Operating cash flow declined for two straight years, from KRW 1,266.0bn in 2023 to KRW 822.3bn in 2024 and KRW 582.9bn in 2025. The debt ratio rose from 31.4% in 2022 to 37.4%, 48.8% and 52.0% in the following years.
Total equity was essentially flat, at KRW 9,358.6bn in 2022 versus KRW 9,336.2bn in 2025, suggesting dividends and share cancellations offset retained earnings. If profit grows without matching cash generation and balance-sheet capacity, the funding structure behind the return policy becomes a point to examine.
Under the Act on Management of Tobacco Harmfulness, effective 1 November 2025, manufacturers and importers must submit each product for harmful-ingredient testing every two years.
Information on products submitted for testing by 31 January 2026 is scheduled for disclosure in the second half of 2026 after committee review. The broadened legal definition of tobacco extends cigarette-centric rules across related laws to all tobacco products.
How ingredient disclosure and wider regulatory scope affect product-level demand and marketing has yet to be observed.
The company said overseas cigarettes kept growing strongly despite uncertainties including the conflict involving Iran. Yuanta Securities said in a July 2026 report that price increases and a higher premium mix were continuing, centered on Russia and Kazakhstan.
The greater the reliance on specific regions, the larger the impact of currency moves, sanctions and logistics disruptions. Expanding local production reduces logistics risk but exposes fixed assets to policy changes in individual countries.
Analysts point to cannibalization risk as NGP expands at the expense of existing cigarette profits, requiring a portfolio strategy that guides consumer migration while protecting high-margin cigarette earnings.
Domestic NGP held a 48.2% share and revenue rose 23.8% as the premium stick mix widened following the launch of lil AIBLE 3.0. If the transition runs faster than the company can manage mix, group margins could be pressured. If it runs too slowly, the growth axis weakens instead.
In the Q3 results, check whether overseas cigarette pricing and volume trends and domestic NGP share hold the Q2 trajectory. It is the quarter that gauges progress toward the raised full-year guidance of 5-7% revenue growth and 10-13% operating profit growth.
A new mid-to-long-term shareholder return policy with strengthened dividends is scheduled for announcement. Key items to check are total return size, the dividend formula, and the mechanics of share cancellation.
Watch for disclosure and size of the second-half treasury share buyback and cancellation the company said would proceed as planned. The scale determines the change in shares outstanding.
Under the enforcement decree of the tobacco harmfulness act, the first implementation plan must be established by 30 November 2026. How the tested ingredients and disclosure scope are finalized may affect product labeling and marketing rules.
This is when FY2026 results and the year-end dividend decision arrive. Since the company said it would consider raising the year-end dividend based on profit growth and return capacity, the actual resolution should be reviewed alongside any recovery in operating cash flow.
KT&G's recent results show it stepping out of a revenue plateau. Annual revenue expanded from the KRW 5.85-5.91trn range in 2022-2024 to KRW 6,579.7bn in 2025, with operating profit reaching KRW 1,343.7bn.
In 2026 operating profit was KRW 364.5bn in Q1 and KRW 414.5bn in Q2, pushing margins higher again, and the company raised full-year guidance to 5-7% revenue growth and 10-13% operating profit growth.
Growth is centered on simultaneous price and volume gains in overseas cigarettes plus a better domestic NGP mix, with a rising share of local production from the new Kazakhstan and Indonesia plants cited as the axis of change in the cost structure.
On the other side sit declining domestic cigarette demand, a setback in overseas health-food sales from Chinese inventory adjustment, two consecutive years of lower operating cash flow and a debt ratio that has risen to 52.0%.
On returns, the schedule is already visible, from the cancellation of treasury shares equal to 9.5% of issued stock to the new policy due in the fourth quarter.
The central question for reading this stock is how far overseas profit growth and a shrinking share count offset the contracting domestic market; this material is for information purposes and contains no buy or sell recommendation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.